On August 6, 2020 InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, reported that it will present at several upcoming virtual investor events in August and September as follows (Press release, InflaRx, AUG 6, 2020, View Source [SID1234563135]):
BTIG Virtual Biotechnology Conference: August 10th – 11th
A BTIG analyst will host a fireside chat with Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, to discuss the Company’s pipeline and upcoming catalysts on Monday, August 10th at 12:30pm EST. The Company will also hold virtual 1X1 meetings.
A live webcast of the fireside chat will be provided on the InflaRx website in the Investors section under Events & Presentations. A replay will be available following the live event.
H.C. Wainwright Annual Global Investment Conference: September 14th – 16th
The Company will give a presentation and conduct virtual 1X1 meetings.
A live webcast of the Company’s presentation will be provided on the InflaRx website in the Investors section under Events & Presentations.
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit: September 21st – 23rd
The Company will give a presentation and conduct virtual 1X1 meetings.
About IFX-1:
IFX-1 is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood. Thus, IFX-1 leaves the formation of the membrane attack complex (C5b-9) intact as an important defense mechanism, which is not the case for molecules blocking the cleavage of C5. IFX-1 has been demonstrated to control the inflammatory response driven tissue and organ damage by specifically blocking C5a as a key "amplifier" of this response in pre-clinical studies. IFX-1 is believed to be the first monoclonal anti-C5a antibody introduced into clinical development. Approximately 300 people have been treated with IFX-1 in clinical trials, and the antibody has been shown to be well tolerated. IFX-1 is currently being developed for various indications, including Hidradenitis Suppurativa, ANCA-associated vasculitis, Pyoderma Gangraenosum and COVID-19 pneumonia.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!